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Summary
Objective: As adult cartilage has very limited potential to regenerate, cartilage repair is challenging. Available treatments have several
disadvantages, including formation of ﬁbrocartilage instead of hyaline-like cartilage, as well as eventual ossiﬁcation of the newly formed tissue.
The focus of this review is the application of bone morphogenetic protein-4 (BMP-4) and mesenchymal stem cells (MSCs) in cartilage repair,
a combination that could potentially lead to the formation of permanent hyaline-like cartilage in the defect.
Methods: This review is based on recent literature in the orthopaedic and tissue engineering ﬁelds, and is focused on MCSs and bone
morphogenetic proteins (BMPs).
Results: BMP-4, a stimulator of chondrogenesis, both in vitro and in vivo, is a potential therapeutic agent for cartilage regeneration. BMP-4
delivery can improve the healing process of an articular cartilage defect by stimulating the synthesis of the cartilage matrix constituents:
type II collagen and aggrecan. BMP-4 has also been shown to suppress chondrogenic hypertrophy and maintain regenerated cartilage.
Use of an appropriate carrier for BMP-4 is crucial for successful reconstruction of cartilage defects. Due to the relatively short half-life
in vivo of BMP-4, there is a need to localize and maintain the delivery of BMP-4 to the injury site. Additionally, the delivery of MSCs to the
wound site could improve cartilage regeneration; therefore, the carrier should function both as a cell and a protein delivery vehicle.
Conclusion: The role of BMP-4 in chondrogenesis is signiﬁcant, and successful methods to deliver BMP-4, with or without MSCs, to the
cartilage defect site are a promising therapy to treat cartilage defects.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Due to a lack of blood supply and limited innervation, human
adult cartilage has a very limited ability to repair1. When
a cartilage defect is treated operatively, formation of
ﬁbrocartilage occurs more often than hyaline-like cartilage,
and the newly formed tissue usually degenerates over
time2. Until recently, cartilage repair research was mainly
focused on autologous chondrocyte implantation (ACI)3,
a cell-based surgical treatment modality, which has given
satisfactory clinical results4, but the concept itself is not
ideal. Firstly, it is a two-step procedure, which includes
donor site morbidity. Secondly, the quantity of available
autologous chondrocytes is limited. Thirdly, chondrocytes
can dedifferentiate into ﬁbroblasts when cultured ex vivo5.
Because of the shortcomings inherent in current treatment
modalities, the research focus in cartilage repair is currently
shifting from using autologous chondrocytes towards the uti-
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1121and growth factors, as well as various combinations of these
three options.
MSCs (derived from bone marrow6, the superﬁcial zone of
cartilage7, periosteum8, synovium9, muscle10 or fat11) are
available in larger quantities and are easier to isolate, culture
and manipulate ex vivo compared to autologous chondro-
cytes. MSCs have the potential to differentiate into various
tissues (including cartilage)6,7,9,10,13 and their capacity for
self-renewal and longevity is substantial.
The bone morphogenetic proteins (BMPs) are a family of
multifunctional growth factors well known for their ability to
induce bone formation (Table I). Recently, BMP-2 and
BMP-7 have been shown to improve cartilage repair when
used in combination with different types of artiﬁcial cartilage
repair plugs comprising either collagen2,4, or hydroxyapatite
blended with biodegradable polymers14. While the majority
of research efforts have focused on BMP-2, BMP-4 is
currently being examined due to its various actions on
mesenchymal stem, namely involving the induction or main-
tenance of cartilage15,16.
A recent study by Kuroda et al. showed that murine mus-
cle-derived stem cells (MDSCs) expressing BMP-4 were
able to produce hyaline-like cartilage which did not degrade
or ossify even after 6 months in a rodent full-thickness artic-
ular cartilage defect10. This study, and others, emphasizes
Table I
BMPs, function/mechanism of action and clinical use
Name Function/mechanism of action Clinical use
BMP-2 Promotes bone formation by inducing
endochondral ossiﬁcation;
Promotes cartilage formation by inducing
production of cartilage matrix
Current:
 Treatment of long bone open fractures
and non-unions114
 Spinal fusion114
Potential:
 Cartilage repair
BMP-3 Inhibits bone formation by inhibiting the
activity of BMP-2114
Potential:
 Treatment of osteopetrosis and other
diseases characterized by
bone hypermineralization
BMP-4 Promotes bone formation by inducing
enchondral ossiﬁcation;
Promotes cartilage formation by inducing
MSCs to become chondroprogenitors and
chondrocyte maturation
Potential:
 Bone repair and fracture healing (especially
at an early point of callus formation)115
 Cartilage repair
 Treatment of OA and RA
BMP-5 Regulates bone homeostasis by
stimulating osteoclast generation116;
Promotes proliferation and cartilage matrix
synthesis in primary chondrocyte cultures117;
Regulates development of ears, rib cage and sternum118
Potential:
 Bone repair
 Cartilage repair
 Treatment of osteoporosis
BMP-6 BMP-6 induces bone formation through an
alternate mechanism compared to BMP-2 or BMP-4119;
Regulates bone homeostasis by stimulating
osteoclast generation;
Promotes chondrogenic differentiation in
adipose-derived stem cells and ligament ﬁbroblast120
Potential:
 Fracture healing
 Cartilage repair
 Treatment of OA and RA
 Treatment of osteoporosis
BMP-7 (OP-1) Promotes bone formation by inducing
enchondral ossiﬁcation;
Promotes cartilage formation by up-regulating
chondrocyte metabolism and protein synthesis121
Current:
 Treatment of non-unions and
long-bone fractures
Potential:
 Spinal fusion
 Cartilage repair
BMP-8 (OP-2) Promotes bone formation, especially active
in the early phase of fracture healing122
Potential:
 Fracture healing
BMP-9 Potent anabolic factor for juvenile cartilage123 Potential:
 Treatment of juvenile cartilage disorders
BMP-12 (GDF7) Modulates in vitro cartilage formation in
a similar fashion as BMP-2 does124
Potential:
 Cartilage repair
BMP-13 (GDF6) Modulates in vitro cartilage formation
in a similar fashion as BMP-2 does124
Potential:
 Cartilage repair
BMP-14 (GDF5,
CDMP-1)
Promotes bone and cartilage formation through
cellular recruitment and chondrocyte differentiation125
Potential:
 Fracture healing
 Cartilage repair
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chondrogenesis both in vitro and in vivo10,17,18, for improv-
ing healing of osteochondral defects, and for maintaining
structure of the regenerated cartilage10.
The aim of this review paper is to discuss BMP-4 as a po-
tential therapeutic agent for cartilage repair by discussing its
biology; its chondrogenic properties; different delivery
systems; and its clinical relevance to osteoarthritis (OA),
rheumatoid arthritis (RA), and traumatic cartilage defect
treatment.Biology of BMPs: signaling and receptors
involved in chondrogenesis
Structurally, BMPs are dimeric molecules with two poly-
peptide chains covalently attached by a single disulﬁdebond19. Functionally, BMPs regulate cell fate determination
and differentiation into different tissue and cell types, includ-
ing MSCs, chondroprogenitor cells and chondrocytes20.
MSCs are less responsive to BMP-induced chondrogenesis
compared to chondroprogenitor cells, most likely because
the pathway of the BMP signal from the transmembrane
receptors to the nucleus differs between the two cell
types20.
The BMP signal which regulates cartilage formation
enters the cell nucleus using one of the two pathways:
a Smad-dependent or a Smad-independent signal trans-
duction pathway (Smad being a family of structurally related
signaling proteins). In a Smad-dependent pathway, BMP
ligands elicit signal transduction through transmembrane,
heterodimeric receptor complexes (including type-I and
type-II serineethreonine kinase receptors). Downstream
from the receptors, the signal is controlled by speciﬁc
1123Osteoarthritis and Cartilage Vol. 16, No. 10regulatory Smad proteins (Smad1, Smad5 and Smad8)
which translocate the original BMP signal to the cell
nucleus in order to transactivate the target genes20. This
signaling system can be inﬂuenced by many positive
(BMP agonists) or negative (BMP antagonists) modulators,
which can be extracellular and intracellular. Extracellular
BMP agonists enhance BMP activity by interacting with
speciﬁc receptors (i.e., EP4 receptor agonist21, BMP acti-
vating co-receptors DRAGON and RGMAa22), while
intracellular agonists interact either with the Smad proteins
(Co-Smads such as Smad422 or Stat323 or with the nuclear
transcription factors (i.e., p30024), GCN525, ZEB-1/delta
EF126).
Extracellular BMP antagonists (noggin, chordin22,
follistatin27 and gremlin28) inhibit BMP’s action by pre-
venting BMP to bind to a speciﬁc transmembrane recep-
tor, while intracellular antagonist intercepts the Smad
cascade either blocking (inhibitory Smads such as
Smad6 and Smad7)22 or only attenuating the BMP signal
(small C-terminal domain phosphatase e SCP)29.
Twisted gastrulation (Tsg) is able to act both as a BMP
agonist and antagonist: as a BMP agonist Tsg counter-
acts chordin’s action and as a BMP antagonist, Tsg
inhibts BMP signaling by directly binding with BMP-2
and BMP-422.
Many mutational studies have been performed to further
clarify the functions of BMPs. Completely knocking-out the
BMP-4 gene in mice was lethal, most probably due to the
lack of mesodermal development30. Conditionally knocking-
out the same gene ended either in bony defects31 or in
the absence of membranous ossiﬁcation (in BMP-2/-4
gene conditional knock-out mice)32. Tsumaki et al.33
showed that over-expression of Noggin gene in transgenic
mice caused a serious decrease in cartilage production,
while over-expression of BMP-4 gene resulted in increased
cartilage production, increased chondrocyte hypertrophy,
and early death.
Similar studies have been conducted to elucidate BMP’s
pathways and receptors. Smad1 null mice died because
the mutant embryos couldn’t connect to the placenta, while
conditional knock-out of Smad1 resulted in a signiﬁcant
decrease of bone volume, proving that Smad1 is a carrier
of BMP bone mass regulation signal22. In humans, over-
expression of BMP-4 and abnormal regulation of BMP
receptor IA (BMPRIA) may lead to progressive ﬁbrodyspla-
sia22. BMPR1B mutations at position 486 have a strong
inhibitory effect on chondrogenesis and osteoblastic differ-
entiation and cause a disturbance in the intracellular Smad
and MAP kinase signalings, resulting in either a brachydac-
tyly type C/symphalangism-like phenotype or brachydac-
tyly type A234.
In addition to a Smad-dependent pathway, there is an
alternative Smad-independent pathway in which BMPs
regulate chondrogenesis by activating several mitogen-
activated protein kinases (MAPKs), including extracellular
signal-regulated kinases (ERKs) and p38 kinases35. The
oligomerization mode of the BMP transmembrane recep-
tors determines which pathway will be activated. The
ligand-induced signaling complexes of BMP receptors
activate the MAP kinase pathway and ligand binding to
preformed hetero-oligomeric BMP receptor activate the
Smad pathway. Both pathways end by inducing the
transcription of speciﬁc target genes in the nucleus34.
Therefore, strategies to manipulate both of these different
BMP signaling pathways could potentially guide implanted
MSCs combined with BMPs to undergo chondrogenesis
instead of endochondral ossiﬁcation.IN VITRO CHONDROGENESIS, MSCs AND BMP-4Recombinant human BMP-4, together with puriﬁed
BMP-3, stimulates chondrogenesis in limb bud mesodermal
cells, showing that BMP-4may play an important role in early
chondrogenesis19 most probably by inducing Runx2 (Runt-
related transcription factor 2) to promote cellular condensa-
tion (together with BMP-2 and BMP-7)36. Furthermore,
BMP-4 enhances the production of articular cartilage matrix
by stimulating the synthesis of collagen type II and aggre-
can17,19 which is important to maintain the articular cartilage
phenotype. To induce chondrogenesis in vitro, a slightly
higher concentration of BMP-4 is needed compared to
in vivo. This can be explained by the fact that in vitro BMP-4
is free in the solution and easy to detect, while in vivo
BMPs are bound to the extracellular matrix, thus the exact
concentration is difﬁcult to determine. This fact is of a great
relevance when using BMPs for bone and cartilage
formation, because the optimal concentration needed is
dependent on the microenviroment19.
BMP-4 plays an important role in maintaining chondro-
genic phenotype, through both enhancing matrix production
and suppressing the production of collagen type X17,19. By
stimulating matrix production, BMP-4 prevents chondrocyte
dedifferentiation, which is a challenge when culturing chon-
drocytes ex vivo. By suppressing the production of collagen
type X, BMP-4 also prevents chondrocyte hyperthrophy.
Together with growth and differentiation factor 5 (GDF5),
a closely related protein family member, BMP-4 accelerates
chondrocyte maturation in vitro37. This is most likely initiated
through an interaction between Runx2 and BMP-activated
Smad138, although Smad5 may act as a mediator as
well39. Inhibitory Smad6 and Smad7 act as a negative feed-
back mechanism that regulates BMP and GDF activities40.
BMP-4 can induce the initial differentiation of MSCs
toward a chondroprogenitor lineage and facilitate differenti-
ation into mature chondrocytes (Fig. 1). GDF5 has similar
effects on MSCs by promoting cell condensation37. The
roles of both BMP-4 and GDF5 in chondrogenesis can be
controlled and limited by BMP antagonists such as noggin
and chordin22. As described brieﬂy above, both noggin
and chordin are extracellular BMP antagonists which have
a high afﬁnity to bind BMPs. This binding prevents the inter-
action of BMPs with speciﬁc receptors, but only noggin
binds both BMP-2, -4, -5, -6 and -7 as well as GDF5 and
GDF622. Exogenously added BMP-4 acts synergistically
with transforming growth factor-b3 (TGF-b3) in inducing
chondrogenesis in MSCs and chondroprogenitor cells41.
Nakayama et al. demonstrated that BMP-4 functions in
a dose-dependent manner41. In their study, 50 ng/mL of
BMP-4 enhanced more cartilage formation compared to
20 ng/mL, while 5 ng/mL was not effective41. For MSCs,
both TGF-b3 and BMP-4 are needed to stimulate
chondrogenesis, while chondroprogenitor cells can undergo
chondrogenic differentiation in the presence of BMP-4 only.
This implies that, under in vitro conditions, TGF-b3 is impor-
tant in the early stages of MSC chondrogenesis, while
BMP-4 has an important role at a slightly later phase (after
24e48 h)42. This time-dependent response may give insight
into the optimal timing of BMP-4 administration when used
for in vivo cartilage repair. Also, BMP-4 activates different
Smad pathways in these two different cell groups and this
may explain the observation that MSCs and chondroproge-
nitor cells react differently to BMP-4. In chondroprogenitor
cells, the chondrogenic differentiation is mediated by
Smad1 and Smad5, while in MSCs, Smad8 has been
shown to be important for chondrogenesis20.
Mature
chondrocyte
MSC Pre-chondrocyte Immature
chondrocyte
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Fig. 1. MSCs, BMP-4 and chondrogenesis.
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sis in vitro in both embryonic and adult stem cell populations
derived from bone marrow43, periosteum44, adipose
tissue11, and muscle10, particularly in a three-dimensional
pellet culture system10,45. The micromass pellet culture
system has been widely used as an in vitro assay for
chondrogenesis but it may not be indicative of the in vivo
chondrogenic capacity46,47. Human adult and embryonic
stem cells respond differently to speciﬁc BMPs, including
BMP-4. In adult bone marrow-derived stem cells, BMP-2 is
most effective in stimulating chondrogenesis as compared
to BMP-4 and BMP-643. Alternatively, BMP-2 and BMP-4
show equivalent efﬁcacy in promoting the chondrogenic dif-
ferentiation of embryonic stem cells, more so than TGF-b148.
Regardless of the methods used to promote the chondro-
genic differentiation of MSCs using BMP-4 (either direct
protein stimulation49 or genetically engineering the cells to
express BMP-410) results cannot translate directly into
in vivo conditions. This discrepancy is mainly due to the
controlled microenviroment in vitro, compared to the in vivo
environment. Also to be considered are the speciﬁc limita-
tions for using cultured MSCs for cartilage engineering
in vivo which include risk of virus and prion transmission (if
the MSCs are cultured with animal serum), reaction to non-
human proteins (if the cells are cultured with animal serum),
uncontrolled chondrocyte hypertrophy, and ﬁbrocartilage for-
mation50.The cartilage tissue cultivated from MSCs in vitro
can be used in either immature or mature forms51. In the
immature form, uncommitted MSCs are usually incorporated
in a bioscaffold. The mature form of cultivated cartilage often
lacks the biomechanical and histological stabilities of a natu-
ral articular cartilage. Furthermore, mature cultivated carti-
lage has poor handling properties including limited ways
to ﬁx and secure the transplant into the cartilage defect51.IN VIVO CHONDROGENESIS, MSCs AND BMP-4Recombinant human (rh) BMP-4 stimulates early chon-
drogenesis in vivo by stimulating chemotaxis of humanperipheral blood monocytes at femtomolar concentrations
and mitogenic action at picomolar concentrations19. As
BMPs are bound to extracellular matrix (ECM) components
(collagen types I and IV, heparin sulfate, heparin, and min-
eral hydroxyapatite), it is very difﬁcult to determine the exact
efﬁcient concentration of BMPs in vivo. Obtaining effective
doses of BMPs is crucial for clinical applications in both car-
tilage and bone repairs. Furthermore, understanding the
effects of spatial regulation of BMPs may also be important.
The effective dosage of BMPs in vivo has been study by
Pang et al.15 and Ahn et al.52. When used within an 8-mm
rat calvarial bone defect, 2.5 mg of rhBMP-4 per defect
was sufﬁcient to induce bone formation15. This concentra-
tion of rhBMP-4 per defect may be greater than the mini-
mum dose threshold, as no signiﬁcant difference in bone
formation was observed between 2.5 mg and the previously
reported dose of 5 mg of rhBMP-4 per defect52. Further
studies are needed to determine the minimal and most
efﬁcient dose of BMP-4 needed for bone and cartilage
formation. While some knowledge regarding the optimal
doses of BMP-4 for bone repair has been gained, efﬁcient
dosages of BMP-4 for cartilage repair are still not known.
In addition to determining the optimal dose of BMP-4 for
cartilage repair, there remain several unknown factors that
may inﬂuence in vivo chondrogenesis. For example,
alginate-encapsulated mesenchymal progenitor cells trans-
fected to produce either BMP-2 or BMP-4 easily undergo
chondrogenic differentiation in vitro17. However, when trans-
planted into athymic nude rats, the cells demonstrated a very
low chondrogenic differentiation potential for at least 4
weeks17. A possible explanation for this phenomenon may
be that chondrogenesis is delayed in vivo and that a longer
transplantation period is necessary for collagen type II
expression. Furthermore, the supply of nutrients and oxygen
to encapsulated cellsmay be limited under in vivo conditions.
It is also important to note that BMPs not only have the
capacity to promote chondrogenesis, but can promote
endochondral ossiﬁcation as well. Therefore, it is possible
that BMPs could induce the newly formed cartilage to be
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potent progenitor cells45. When MDSCs transduced to
express BMP-4 were implanted into either the thigh muscle
or a calvarial defect of immunocompetent syngeneic mice,
endochondral bone formation occurred53. But when BMP-
4 was delivered locally by genetically engineered MDSCs
to an articular cartilage defect in rats, chondrogenesis
occurred10, with no ossiﬁcation of the newly formed tissue
up to 24 weeks postoperatively. However, ossiﬁcation was
not assessed at time periods beyond 24 weeks after this
type of treatment10. Together, these data suggest that the
effects of microenvironment on MSCs tranduced to secrete
BMPs determined the tissue fate (bone or cartilage) and
that the optimal duration of transgene expression may be
crucial to generate mature articular cartilage54.
There remain several uncertainties regarding MSC’s
chondrogenic differentiation in vivo. At this point, a chal-
lenge is to provide an optimal microenvironment for
cartilage repair in vivo that will induce hyaline-like cartilage
formation and prevent ossiﬁcation at a later time point.EFFECTS OF MICROENVIRONMENT ON THE
CHONDROGENESIS OF MSCsDependingon the typeof treatmentmodality used, themicro-
environmental conditions that affect chondrogenesis include:
(1) culture conditions, (2) mechanical conditions, (3) site of im-
plantation, and (4) type of bioscaffold or local delivery system.
Culture conditions
Culture conditions such as culture medium and growth
factor supplements are crucial for MSC differentiation
toward a speciﬁc lineage. To induce chondrogenesis of
MSCs, various combinations of culture medium reagents
and growth factors have been used. Some medium formu-
lations comprise only regular plating medium combined with
dexamethasone and TGF-b3,47 while others are a more
complex medium including high-glucose Dulbecco’s modi-
ﬁed eagles medium (DMEM) supplemented with dexameth-
asone, sodium pyruvate, ascorbate-2-phosphate, proline,
insulinetransferrineselenium-Premix and L-glutamine10.
The type of growth factor used in vitro to induce chondro-
genesis depends mainly on the type of MSCs. To stimulate
the chondrogenic differentiation of bone marrow-derived
MSCs, various growth factors have been used in isolation
or in combination: TGF-b347, insulin growth factor-1
(IGF-1)55, TGF-b156, BMP-256, and ﬁbroblast growth fac-
tor-2 (FGF-2)57. BMP-4 has been successfully used10 for
the chondrogenic differentiation of muscle-derived MSCs,
while periosteum-derived MSCs seemed most responsive
to TGF-b313. Synovium-derived MSCs can be differentiated
into a chondrogenic lineage via the combination of two
potent chondrogenic stimulators: BMP-2 and TGF-b358.
Adipose-derived MSCs undergo chondrogenic differentia-
tion when cultured with: TGF-b111, BMP-259 or BMP-660.
9-Hydroxyoctadecadienoic acid (9-HODE)61 may be added
to the culture medium to stimulate primary chondrocyte
proliferation and ECM synthesis. Additionally, low oxygen
conditions (5% O2) promote chondrogenesis in many types
of MSCs (except adipose-derived)62 more efﬁciently than
hyperoxic conditions (20% O2)
63.
Mechanical conditions
Mechanical compression64,65, hydrostatic pressure66,67,
shear stress68, low intensity ultrasound (LIUS)69,70,tension71, microgravity72 and extracorporeal shock waves
(ESWs)73 have all been reported to enhance or promote
chondrogenesis in dedifferentiated chondrocytes or in
MSCs in vitro. Although little is known of the role of
BMP-4 in mechanoreceptor-induced pathways during
chondrogenesis, BMP-4 expression during osteogenesis
is increased by the application of tensile stress or ESW
and decreased when the combination of pulsed ultrasound
and shear stress is applied73e76.
In vivo, mechanical stimulation seems to be crucial for
cartilage repair. In a recent rat study, defects exposed to
normal and low load bearing healed with partial regenera-
tion of hyaline-like cartilage, with a higher rate of subchon-
dral bone reformation in a normal load bearing group. In
immobilized knees, only bulges of ﬁbrous tissue formed in
the defects. These results suggest that mechanical stimuli
have positive effects on cartilage repair and that the contact
between the defect and the surface cartilage may play an
important role in the hyaline cartilage repair77. Duda
et al.78 reported a strong connection between the histolog-
ical outcome of an osteochondral knee defect repair and
different mechanical environments in Yucatan minipigs.
Firstly, it was observed that osteochondral defect healing
occurred under normal loading conditions (all animals
returned to full weight bearing only 2 weeks after the
surgery). Secondly, they observed an important pattern of
osteochondral defect repair: new bone formed from the
edges, while the bone at the base of the defect underwent
resorption. Thirdly, at the 12 week time point, macroscopi-
cally healed defects were ﬁlled with ﬁbrous cartilage,
minimally organized trabecular structure and increased
trabecular volume fraction compared to the controls.
Speciﬁc mechanical strains induced speciﬁc combinations
of tissues: cancellous, cartilaginous and ﬁbrous tissues at
particular time points: 4, 6 and 12 weeks. Lastly, at 12
weeks, even though the osteochondral defects seemed to
be healed macroscopically, the defects were undergoing
a remodeling process, which substantially increased the
stiffness of the subchondral portion of the defect. The
authors hypothesized that this phenomenon may have
been the cause of the observed tissue degeneration.
The location of a cartilage defect in vivo signiﬁcantly
inﬂuences the results of different cartilage repair tech-
niques, likely due to differences in mechanical loading in
different knee regions. For example, ACI is a more success-
ful treatment when used to treat cartilage defects located on
the femoral condyles compared to the retropatellar region of
the knee79.
Site of implantation
The site of implantation, together with the type of bioscaf-
fold used as a cell carrier matrix, can signiﬁcantly inﬂuence
MSC differentiation (e.g., bone vs cartilage). Shen et al.53
demonstrated that MDSCs, transduced to secrete BMP-4
and embedded in a 5-mm Gelfoam disk scaffold, differenti-
ated into bone tissue 3 weeks postoperatively when im-
planted in a mouse calvarial bone defect. Conversely,
when implanted into a full-thickness articular cartilage
defect, the same type of cells (MDSC-BMP-4) embedded
in a ﬁbrin glue matrix differentiated into cartilage 4 weeks
after implantation10.
When using MSCs, with or without various growth factors,
to treat articular cartilage defects, there are differences be-
tween chondral defects that involve only cartilage, and os-
teochondral defects, which involve both cartilage and the
underlying bone. Osteochondral defects, unlike chondral
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and signaling factors of subchondral bone origin, which can
eventually lead to bone formation instead of hyaline-like
cartilage formation80. In order to prevent superﬂuous bone
formation, a functional or structural barrier can be used in
addition to MSCs/growth factor treatment. A functional
barrier in the form of an anti-angiogenic factor incorporated
into the artiﬁcial chondrogenic matrix can prevent vascular
ingrowth and subsequent bone formation. Also, bone
formation can be prevented by inserting a cell- and blood
vessel-excluding membrane at the base of the defect81,82.
Type of bioscaffold or local delivery system
Various biomaterials have been used as bioscaffolds for
articular cartilage repair: collagen, gelatin, ﬁbrin, polymers
of polylactic/polyglycolic acid, agarose, alginate, hyalur-
onan, chitosan, carbon ﬁbers, poly(methyl methacrylate),
hydroxyapatite, polyurethane, polymers of butyric acid83
and poly(3-caprolactone) (PCL) nanoﬁbers84,85.
Biphasic grafts have been constructed to promote the
healing of both tissue types involved in an osteochondral
defect: cartilage and bone. In a biphasic graft, the superﬁ-
cial layer of the graft should induce cartilage repair, while
the deep layer should induce bone regeneration. Tanaka
et al. examined a biphasic graft composed of a b-tricalcium
phosphate block as the subchondral layer, and a collagen
gel mixed with chondrocytes as the superﬁcial layer to
repair rabbit osteochondral defects86. Potentially, the
superﬁcial layer of a biphasic graft may be used not only
as a bioscaffold for host chondrocytes, but also for the
delivery of either MSCs or growth factors that may promote
cartilage repair. At the same time, growth factors promoting
bone repair, e.g., the clinically approved bone-inducing
BMP-2, may be incorporated into the deep portion of the
graft to assist with healing of the bony part of the defect87.
A similar concept has been reported by Tamai et al.14, who
developed a tri-composite graft composed of a synthetic
biodegradable polymer combined with BMP-2 as the super-
ﬁcial layer of the graft, and hydroxyapatite as the deep layer
of the graft. In that study, a cell-free implant combined with
BMP-2 induced the repair of an osteochondral defect in
rabbits within 3 weeks14.
Carriers or local delivery systems used for cartilage repair
should meet several requirements. The delivery system
should (1) have the ability to incorporate and release
various signaling substances (growth factors), (2) have suf-
ﬁcient porosity to allow cell migration, (3) be biocompatible,
and (4) be biodegradable. Furthermore, carriers should
have a sufﬁcient volume stability to create a smooth surface
contour for tissue repair and to ensure integration between
newly formed and native tissues. Internal cohesiveness to
prevent matrix outﬂow, elasticity to withhold dynamic and
static deformations, as well as structural anisotropy to
promote native anisotropic tissue organization are addi-
tional important characteristics of an optimal local delivery
system for cartilage repair88.
If a carrier is in a liquid form during clinical application and
gels quickly in situ, the carrier could be applied through an
arthroscopic or minimally invasive surgical procedure. How-
ever, if the local delivery system is in a solid state and can
only be press-ﬁtted into the cartilage defect, the carrier has
to be applied through an arthrotomy (opening the joint) or
a more invasive surgical procedure88. From a clinical
perspective, the implantation of an injectable gel is much
less invasive as compared to a solid graft, and thus is
a better option for the patient, resulting in less morbidity.Local delivery systems are of utmost importance because
BMPs (as well as many other growth factors) have relatively
short half-lives in vivo. Delivery to the exact site of injury
may prolong BMP bioactivity. Furthermore, due to of the
temporal nature of the effects of BMPs, it is essential that
delivery systems be developed that precisely control the
release kinetics of BMPs.APPROVED AND FUTURE LOCAL DELIVERY
SYSTEMS FOR BMP-4Absorbable collagen sponge (ACS) is an FDA-
approved, biodegradable scaffold often used as a BMP
carrier. Pang et al. used both an ACS and b-tricalcium
phosphate (b-TCP) as a local delivery system of
rhBMP-4 for bone formation in rat calvarial defects15.
After 8 weeks, rhBMP-4 delivered to an 8-mm calvarial
defect through b-TCP produced more bone than rhBMP-4
via an ACS. However, the bone that formed de novo in
the rhBMP-4/ACS group had signiﬁcantly greater bone
density than the bone formed in the rhBMP-4/b-TCP
group. These results led to the conclusion that both
ACS and b-TCP are effective delivery systems for
rhBMP-4 mediated bone formation15. Keeping in mind
that these two delivery systems have completely different
structures (ECM protein vs variation of hydroxyapatite)
and different degradation rates, it is difﬁcult to discern
which of these two scaffolds would be more efﬁcient in
delivering BMP-4 to a cartilage defect.
Fibrineﬁbronectin sealing system (FFSS) is an alterna-
tive rhBMP-4 carrier for bone formation. Han et al.89
induced bone formation in an 8-mm rat calvarial bone defect
using this type of carrier (alone or combined with rhBMP-4),
but the level of bone density was signiﬁcantly higher in the
rhBMP-4/FFSS group, as compared to defects treated with
FFSS alone. These results suggest not only that BMP-4 is
a potent stimulator of osteogenesis in calvarial defects,
but also that bioscaffolds combined with growth factors
may be more efﬁcient in promoting bone repair than bio-
scaffolds alone. Both of these studies 15,89 were designed
to assess carriers that permit BMP-4 to be used for bone
repair. The speciﬁc characteristics and comparisons of
carriers of BMP-4 for cartilage repair in vivo have yet to
be determined.
Ultrahigh-viscosity alginate has been used by Steinert
et al. to encapsulate mesenchymal progenitor cells
transfected with BMP-4 which have shown very high chon-
drogenic differentiation potential in vitro17. However, when
transplanted in vivo, this combination of BMP-4 transfected
cells and an alginate-based bioscaffold lost its chondro-
genic potential signiﬁcantly17. These results emphasize
the fact that the translation from in vitro to in vivo is not
straightforward and requires extreme caution.
Microspheres or hydrogels permit controlled release of
growth factors over an extended period of time and may
be useful BMP-4 delivery systems for cartilage repair. Until
recently, only BMP-7 and BMP-2 have been delivered in
this fashion. BMP-7 was delivered to cultivate human
chondrocytes in a collagen type-I gel90, and BMP-2 was
used to treat calvarial bone defects in rats90,91. In both
cases, the efﬁciency of BMPs was increased signiﬁcantly
using the mixed microsphere and ECM delivery system.
Our group has been examining polymer-based delivery
systems for controlled growth factor and protein
delivery92e96. Our strategy for controlled release includes
incorporating microspheres loaded with growth factors
or other active proteins into hydrogels and scaffolds
1127Osteoarthritis and Cartilage Vol. 16, No. 10composed of either native or synthetic polymers. The main
advantage of such a delivery system is that improved
control of encapsulated growth factor release kinetics is
possible. Various parameters of the delivery system can
be modiﬁed. For example, changing the concentration of
the cross-linking agent can result in either a slower or faster
release of growth factor, depending on the system. Addi-
tionally, the size of the microspheres can affect release,
with smaller diameter microspheres typically resulting in
a faster release. Finally, the bioscaffold itself can affect
the release kinetics due to surface interactions with the
hydrogel. These systems represent a promising future ther-
apy for both bone and cartilage repairs.
Gene transfer is a promising delivery system for different
signaling substances, including BMPs. This method of
delivery overcomes many of the problems connected with
direct delivery of growth factors. Most importantly, gene
transfer can alleviate the need for high doses of growth
factors and/or their repeated administration, which can be
therapeutic to one organ while damaging the others97.
MSCs could be transduced or transfected to secrete a par-
ticular type of BMP using either a viral or a non-viral vector
(polymers and liposomes). Once successfully transduced or
transfected, the MSCs could be placed at the site of a bone
or cartilage defect to induce repair98. The main concern of
delivering genes through a viral vector is safety (risk of
insertional mutagenesis99, liver damage100 and immune
system response100,101). However, if the viral vector is
used ex vivo, there may be less risk of various reactions
to the virus. On the other hand, non-viral vectors, which
are very safe, have much lower transfection efﬁciencies
compared to viral vectors (40e50% compared to
80e90%). Goomer et al.102 were able to obtain 71%
transfection efﬁciency in vitro, using poly-L-lysine lipids as
non-viral vectors, in a multi-step transfection process. This
example illustrates that the major disadvantage of non-viral
vector use in gene delivery (low efﬁciency) could soon be
overcome, transforming gene transfer into a safe and
efﬁcient method of delivering growth factors for different
therapeutic purposes, including cartilage repair.Clinical relevance of BMP-4 and MSCs to OA,
RA and traumatic cartilage defect treatment
OA is a progressive, degenerative disease of the joints
characterized by cartilage destruction, and is mainly associ-
ated with aging. Although very little is known about the role
of BMPs in OA pathophysiology, it is known that BMP
antagonists are expressed and regulated differently in
normal and OA chondrocytes103. In OA chondrocytes,
expression of follistatin and gremlin (BMP antagonists
located in the superﬁcial layer of cartilage) is upregulated,
compared to normal chondrocytes103. These BMP antago-
nists could play different roles during various stages of
OA progression. Both BMP-4 and BMP-2 modulate the
expression of these antagonist: stimulating the expression
of gremlin and down-regulating that of follistatin, which is
strongly linked to the inﬂammatory aspect of OA103. Due
to the ability to down-regulate the expression of follistatin,
both BMP-4 and BMP-2 may be potentially used in OA
treatment as anti-inﬂammatory agents.
Chondrocyte sensitivity to various signaling substances
is age-dependent in vitro. Therefore, it seems logical that
chondrocyte sensitivity may be age-dependent in vivo
considering that OA occurs mostly in the elderly population.
This interesting fact may inﬂuence our understanding of themolecular signaling balance in OA104e106. BMP-4, BMP-2,
and BMP-7 have an anabolic role in proteoglycan synthesis
and are thus crucial for chondrogenesis, but the sensitivity of
articular chondrocytes to BMP signaling may be signiﬁcantly
reduced with age. To render BMPs beneﬁcial for cartilage
repair in OA, this may be the ﬁrst obstacle to surpass. Addi-
tionally, the expression of each BMP (BMP-2 to BMP-15) in
synovial tissue can be signiﬁcantly affected under different
pathological joint conditions, but the expression of BMP-4
and BMP-5 mRNA is signiﬁcantly decreased in patients
with OA and RA107. In normal joints, the expression of
BMP-4 and BMP-5 is needed for the formation of a normal
synovial lining layer107. Therefore, adding BMP-4 and
BMP-5 to the joints of patients with OA and RA could be
beneﬁcial. However, the prerogative for this is tomore clearly
understand BMP’smechanism of action and regulation in the
speciﬁc cell types of the joint. Toward that end, Van Beunin-
gen et al. demonstrated that intra-articular injection of BMP-2
induces osteophyte formation in a murine joint model108.
Furthermore, BMP-4, together with BMP-2, appears to be
released by macrophages of the synovial lining layer and
may be involved in osteophyte formation as a downstream
mediator of TGF-b109. Inhibition of BMP-4 and BMP-5 signal-
ing may prevent osteophyte formation and be used as a po-
tential therapeutic strategy in OA. However, such a strategy
may cause damage to the articular cartilage by increasing
the loss of proteoglycans from the cartilage matrix110. This
example emphasizes the fact that a full understanding of
the effects of BMPs is needed prior to use as therapeutic
agents for the treatment of OA and RA.
Another approach to slow down the OA process is to use
MSCs either as a direct intra-articular injection or incorpo-
rated into different bioscaffolds (hydrogels or plugs) to treat
cartilage defects. Murphy et al. treated a surgically induced
OA in goat knees with a direct intra-articular injection (10
million autologous MSCs suspended in sodium hyaluronan)
and observed meniscal regeneration and inhibited disease
progression 6 weeks after cell implantation111. Such results
offer strong support for the possibility of using autologous
MSCs to reverse the progression of OA.
Although the implantation of autologous chondrocytes
(ACI) has demonstrated satisfactory clinical results in the
treatment of traumatic cartilage defects, many issues
surrounding the use of ACI still need to be addressed.
One of these issues stems from the fact that the number
of available autologous chondrocytes is limited due to
a scarcity of healthy cartilage within the donor. Using
MSCs for implantation would alleviate this problem because
(1) MSCs are more readily available and yield a much
higher number of cells, and (2) MSCs can be cultured and
expanded ex vivo much more easily than primary autolo-
gous chondrocytes. Another signiﬁcant issue related to
ACI is that chondrocytes are terminally differentiated and
have a limited life span. MSCs, on the other hand, can be
differentiated into various types of tissue and have
a much longer life span than chondrocytes in vitro, and,
presumably, in vivo112. One of the potential challenges of
using MSCs is the tendency to form ﬁbrocartilage. In vitro
studies have shown, however, that MSCs are able to form
hyaline-like cartilage when they are cultured with speciﬁc
growth factors (e.g., TGF-b or BMP-4)50.
Finally, another important factor that should be addressed
when developing treatments for OA, RA, or traumatic
cartilage defects that involve MSCs is the speciﬁc culture
conditions needed in vitro to increase cell number. One of
the standard cell culture medium supplements is serum de-
rived from non-human animals, usually of bovine origin (fetal
1128 N. D. Miljkovic et al.: Chondrogenesis, bone morphogenetic protein-4 and mesenchymal stem cellscalf or bovine serum). In vitro MSC expansion techniques
should be developed that exclude animal sera in order to
eliminate the potential risk of viral and prion transmissions
and of immune reaction to non-human proteins50.Conclusion
The role of BMPs and MSCs in chondrogenesis is
relevant for developing future cartilage repair therapies.
The capacity of BMP-4 to stimulate aggrecan and collagen
type II synthesis, to suppress chondrogenic hypertrophy, as
well as to accelerate chondrocyte maturation in vitro,
suggests that BMP-4 represents a promising agent for
promoting cartilage repair in the future. Additionally, the
use of autologous MSCs will likely prove effective for carti-
lage repair. Modulation of BMP signaling may also become
an important therapeutic approach in chronic joint diseases
(e.g., OA or RA). BMP signal regulation, including BMP-4
signaling, can inﬂuence the balance between destructive
and reparative forces in the joint113.
In conclusion, the role of BMP-4 and adult MSCs in chon-
drogenesis is potentially signiﬁcant. Successful methods to
deliver either BMP-4 alone or in combination with MSCs to
the cartilage defect site are a promising therapy to treat
cartilage defects.Conﬂict of interest
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